Medical Condition News

RSS

75% increase in cancer incidence predicted by 2030

The global cancer burden is set to surge more than 75% by 2030, according to new research published Online First in the Lancet Oncology. The rise is predicted to be even larger in the developing world, with the poorest countries experiencing a projected increase of more than 90%.

1 Jun 2012

Zinc supplementation in young children with serious infections significantly lowers risk of treatment failure

Treating young children with suspected serious bacterial infection with zinc in addition to standard antibiotics significantly reduces the likelihood of treatment failure, according to new research published Online First in The Lancet. In 2010, worldwide, infections were responsible for nearly two-thirds of deaths in children under 5, with around two-fifths of deaths occurring within the first month of life.

1 Jun 2012

Tentative deals forged in ill., Providence, R.I., to save money on retiree pensions, health care

Officials report accords with public employees restricting pension increases in order to keep the programs solvent. Both deals also involve changes to retiree health care programs..

1 Jun 2012

Innovative model of dementia is now been used to treat over 1,000 patients

An innovative model of dementia care that significantly reduces emergency department visits and hospitalizations, and encourages use of medications that are not harmful to older brains, has now been used to treat over 1,000 patients. The Aging Brain Care model was developed by researcher-clinicians from the Regenstrief Institute and the Indiana University School of Medicine.

1 Jun 2012

Researchers discover binding partner of TDF hormone

Researchers at Clarkson University in Potsdam, N.Y., led by Chemistry & Biomolecular Science Professor Costel C. Darie, in collaboration with researchers from Columbia University, have now found the binding partner of TDF, a pituitary hormone that had previously been shown to reduce cancer progression in breast cancer cells, in prostate cancer as well.

1 Jun 2012

JSUMC completes first procedure with TAVR

Jersey Shore University Medical Center proudly announces the completion of its first procedure with the Transcatheter Aortic Valve Replacement (TAVR), the latest minimally-invasive, life-saving innovation for non-operative patients with critical aortic stenosis.

1 Jun 2012

Target of 25% reduction in premature mortality from NCDs by 2025 a 'rallying call' for global health community

Member states at the 65th session of the World Health Assembly, which concluded last week, "agreed to adopt a global target of a 25 percent reduction in premature mortality from non-communicable diseases [NCDs] such as cardiovascular disease, cancer, diabetes and chronic respiratory diseases by 2025."

1 Jun 2012

JMC publishes results from Rexahn’s RX-3117 preclinical cancer study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry on the anti-tumor activity of its RX-3117 compound.

1 Jun 2012

Personalized medicine and the Human Genome Project

It’s nearly a decade since the completion of the Human Genome Project, (1) which aimed to sequence the complete human genome.

1 Jun 2012

Beta-carotene safe to use during radiation therapy for prostate cancer

Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the May issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology.

1 Jun 2012

N-of-One develops unique knowledge integration platform for oncologists

N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has developed a unique knowledge integration platform to enable care providers and patients to make informed decisions about diagnostic and treatment strategy.

1 Jun 2012

LILRB2 receptor plays an important role in keeping stem cells from differentiating

An immune-system receptor plays an unexpected but crucially important role in keeping stem cells from differentiating and in helping blood cancer cells grow, researchers at UT Southwestern Medical Center report today in the journal Nature.

1 Jun 2012

ImmunoCellular to present new data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

1 Jun 2012

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

1 Jun 2012

Scientists succeed in solving first structure of a Wnt protein

The 20 proteins in the Wnt family are some of the most important proteins in controlling how an organism develops and grows, but for 30 years scientists have not known what these vital proteins actually look like. The proteins have eluded standard visualization techniques, in large part because they do not dissolve well in the water-based liquids normally used for biochemical studies.

1 Jun 2012

Functional disability impacts educational attainment in children with JIA

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

1 Jun 2012

Researchers uncover potential new way to regulate the body's natural immune response

Australian researchers have uncovered a potential new way to regulate the body's natural immune response, offering hope of a simple and effective new treatment for auto-immune diseases.

1 Jun 2012

Top-line results from Genzyme’s teriflunomide Phase III trial on MS

Genzyme, a Sanofi company, announced today top-line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once-daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis.

1 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Ventana Medical Systems, Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.

1 Jun 2012